Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Elise A. Olsen(Duke University), Julia Scarisbrick(NIHR Surgical Reconstruction and Microbiology Research Centre), José Antônio Sanches(Universidade de São Paulo), Alejandro A. Gru(University of Virginia), Madeleine Duvic(The University of Texas MD Anderson Cancer Center), H. Miles Prince(Monash University), Robert Knobler(Medical University of Vienna), Pablo L. Ortiz‐Romero(Research Institute Hospital 12 de Octubre), Werner Kempf(University Hospital of Zurich), Wei Ai(University of California, San Francisco), Gary S. Wood(Peter MacCallum Cancer Centre), Emmilia Hodak(European Organisation for Research and Treatment of Cancer), Lawrence Schwartz(Columbia University Irving Medical Center), Michael Girardi(Yale University), Pietro Quaglino(Department of Medical Sciences), John A. Zic(Vanderbilt University), Evangelia Papadavid(National and Kapodistrian University of Athens), Makoto Sugaya(National Cancer Institute), M. Bagot, Rein Willemze(Leiden University Medical Center), Emmanuella Guenova(University of Zurich), Mark R. Pittelkow(Mayo Clinic in Arizona), Lauren Pinter‐Brown(University of California, Irvine), Maarten H. Vermeer(Leiden University Medical Center), Richard T. Hoppe(Stanford University), Joan Guitart(Peter MacCallum Cancer Centre), Mary Jo Lechowicz(Emory University), Francine M. Foss(Peter MacCallum Cancer Centre), Sean Whittaker(Guy's Hospital), Sarah McCue Horwitz(Memorial Sloan Kettering Cancer Center), Ellen Kim(Peter MacCallum Cancer Centre), Jasmine M. Zain(City Of Hope National Medical Center), Rudolf Stadler(Johannes Wesling Klinikum Minden), Youn H. Kim(Cancer Prevention Institute of California), Larisa J. Geskin(University of Pittsburgh)
Cited by 170
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610
Mental Health Service Use in the Community and Schools: Results from the Four-Community MECA Study
|Journal of the American Academy of Child & Adolescent Psychiatry|1996|609